GYRO
Gyrodyne, LLC9.17
+0.00+0%
Dec 15, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
20.17MP/E (TTM)
43.68Basic EPS (TTM)
0.21Dividend Yield
0%Recent Filings
8-K
Flowerfield deal amended
Gyrodyne's subsidiary GSD Flowerfield amended its July 2025 purchase agreement with B2K Smithtown on January 6, 2026, crediting $1,520,222 toward the purchase price for on-site improvements to Flowerfield Lots 1 and 3 at closing, while B2K handles all common facilities and offsite work. Investigation period expired; B2K waived termination rights there. Third-party covenants must resolve by February 5, or B2K can walk with deposit returned. Timeline uncertain.
10-Q
Q3 FY2025 results
Gyrodyne's net assets in liquidation climbed to $32.4M as of September 30, 2025, up 5.8% from $30.6M year-end 2024, lifting estimated distributions to $14.72 per share from $13.91 (derived). Real estate held for sale jumped $4.5M to $54.9M, fueled by the July 2025 B2K deal for a 49-acre Flowerfield parcel at up to $28.7M contingent on subdivision and site plan nods expected by late 2027. Cash sits at $5.1M while loans payable total $10.9M across fixed-rate facilities maturing 2026-2028. Article 78 appeal drags on. Approvals remain uncertain.
8-K
Annual meeting results reported
Gyrodyne held its 2025 annual meeting on November 5, with 66.5% of shares present. Shareholders elected Richard B. Smith as director for three years (1.39M for, 30K withhold), approved exec compensation advisory (1.39M for), and ratified Baker Tilly as auditors (1.44M for). Routine governance upheld.
8-K
Flowerfield sale contract signed
Gyrodyne signed a July 2025 contract to sell 49 acres at Flowerfield for $28.74 million gross, closing end-2027 if entitlements clear post-Article 78 resolution. Costs exceeded receipts by $700,000 in H1 2025, pro forma NAV per share fell to $14.83 from $15.98. Litigation drags on. NAV holds steady.
8-K
Gyrodyne settles board dispute
Gyrodyne locked in a deal with Star Equity on October 16, 2025, pulling their board nomination threat in exchange for slashing the board from five to four directors and capping chairman fees at $65,000. Star Equity commits to backing board picks until 2026—or 2027 if key directors re-up—while standstill rules curb proxy fights. A separate pact with Leap Tide and directors seals similar voting support through 2028. Board shrinks fast. This settles activist noise, steadying governance amid property sale pushes, though litigation risks linger.
AOXY
Advanced Oxygen Technologies, I
0.08+0.00
BALDF
FASTIGHETS AB BALDER
6.76+0.00
BRST
Broad Street Realty Inc.
0.01+0.00
CPTP
Capital Properties, Inc.
12.10+0.10
DEA
Easterly Government Properties,
22.26-0.16
EUDA
Euda Health Holdings Limited
2.40+0.14
MAYS
J. W. Mays, Inc.
38.25+0.00
NYC
American Strategic Investment C
7.85+0.29
SLG
SL Green Realty Corp
45.75+0.16
ZDPY
Zoned Properties, Inc.
0.48+0.00